复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

圣诞节后第一个工作日休市 12-24 12:08:29

14.020

+0.140

+1.01%

最高14.060	最低13.820	成交量113.20万
今开13.820	昨收13.880	日振幅1.73%
总市值373.63亿	流通市值76.55亿	总股本26.65亿
成交额1,584万	换手率0.21%	流通股本5.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":14.02,"timestamp":1735013309015,"preClose":13.88,"halted":0,"volume":1132000,"delay":0,"floatShares":546000000,"shares":2665000000,"eps":0.95009774,"marketStatus":"圣诞节后第一个工作日休市","marketStatusCode":7,"change":0.14,"latestTime":"12-24 12:08:29","open":13.82,"high":14.06,"low":13.82,"amount":15835680,"amplitude":0.017291,"askPrice":14.02,"askSize":12500,"bidPrice":13.96,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.8315278013888026,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1735263000000},"adr":0,"listingDate":1351526400000,"adjPreClose":13.88,"dividendRate":0.020564,"openAndCloseTimeList":[[1735003800000,1735012800000]],"volumeRatio":1.2461634089439162,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":25.51,"timestamp":1735176939000,"preClose":25.6,"halted":0,"volume":427903,"delay":0,"premium":"-48.30"}},"requestUrl":"/m/hq/s/02196/tweets","defaultTab":"tweets","newsList":[{"id":"2494008204","title":"上海复星医药产业发展有限公司申请II类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2494008204","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494008204?lang=zh_cn&edition=full","pubTime":"2024-12-26 07:23","pubTimestamp":1735169004,"startTime":"0","endTime":"0","summary":"金融界12月26日消息，据CDE官网沟通交流公示，于12月26日收到上海复星医药产业发展有限公司申请的“II类会议”，当前状态“处理中”。根据《药物研发与技术审评沟通交流管理办法》（2020年第48号通告），沟通交流会议分为Ⅰ类、Ⅱ类和Ⅲ类会议，就关键阶段重大问题进行沟通交流。Ⅱ类会议一般安排在申请后60日内召开，系指为药物在研发关键阶段而召开的会议，主要包括下列情形：新药临床试验申请前会议、药物Ⅱ期临床试验结束/Ⅲ期临床试验启动前会议、新药上市许可申请前会议、风险评估和控制会议。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2024/12/26072346824346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0187","BK1593","02196","BK0175","BK0183","BK0060","BK1191","BK0196","BK0028","BK0012","BK0096","600196","BK0239","BK1515","BK0188"],"gpt_icon":0},{"id":"2494046378","title":"复星医药收盘下跌0.35%，滚动市盈率32.35倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2494046378","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494046378?lang=zh_cn&edition=full","pubTime":"2024-12-25 18:44","pubTimestamp":1735123465,"startTime":"0","endTime":"0","summary":"12月25日，复星医药今日收盘25.6元，下跌0.35%，滚动市盈率PE达到32.35倍。从行业市盈率排名来看，公司所处的化学制药行业市盈率平均44.61倍，行业中值27.40倍，复星医药排名第93位。截至2024年三季报，共有49家机构持仓复星医药，其中基金44家、其他4家、社保1家，合计持股数113959.43万股，持股市值315.33亿元。上海复星医药(集团)股份有限公司主营业务是制药、医疗器械、医学诊断、医疗健康服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225184658984eb068&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225184658984eb068&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0096","600196","BK0183","BK0188","BK0012","BK0196","BK0239","BK0028","BK0175","BK0060","02196","BK0187"],"gpt_icon":0},{"id":"2494404311","title":"豫园股份：控股股东复星高科技下属复地投资和复星商业质押共计3.9亿股用于偿债","url":"https://stock-news.laohu8.com/highlight/detail?id=2494404311","media":"北京商报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494404311?lang=zh_cn&edition=full","pubTime":"2024-12-25 18:10","pubTimestamp":1735121400,"startTime":"0","endTime":"0","summary":"北京商报讯(记者蔺雨葳)12月25日，豫园股份发布公告，控股股东上海复星高科技(集团)有限公司下属上海复地投资管理有限公司和浙江复星商业发展有限公司办理股票质押。复地投资本次质押2亿股，占其所持股份比例的19.54%，占公司总股本比例的5.14%；复星商业本次质押1.9亿股，占其所持比例的52.03%，占公司总股本比例的4.88%。质押起始日均为2024年12月24日，质押到期日均为2026年12月23日，质押融资资金用途均为偿还债务。2024年前三季度，豫园股份实现收入361.01亿元，归母净利润11.59亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225181638ab91e137&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225181638ab91e137&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1593","BK1515","BK1191"],"gpt_icon":0},{"id":"2493874151","title":"南向资金12月23日净买入复星医药13.85万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2493874151","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493874151?lang=zh_cn&edition=full","pubTime":"2024-12-24 09:30","pubTimestamp":1735003820,"startTime":"0","endTime":"0","summary":"12月23日, 南向资金增持复星医药13.85万股，连续5日增持。截止当日收盘，港股通共持有复星医药31000.40万股，占流通股56.15%。复星医药近5个交易日下跌1.14%，港股通累计增持323.75万股；近20个交易日下跌0.86%，港股通累计增持636.74万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224093509a2062d7e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224093509a2062d7e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1593","BK1515","BK1191"],"gpt_icon":0},{"id":"2493461387","title":"复星医药(02196.HK)：吸收合并复宏汉霖(02696.HK)前提条件已达成","url":"https://stock-news.laohu8.com/highlight/detail?id=2493461387","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493461387?lang=zh_cn&edition=full","pubTime":"2024-12-24 08:59","pubTimestamp":1735001940,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，截至上周一(16日)，就对控股子公司复宏汉霖(02696.HK) 实施吸收合并及私有化交易协议生效的前提条件均已达成，当中包括取得国家发改委及其他主管部门审批、备案或登记等。复宏汉霖将于2025年1月22日召开临时股东大会及H股类别股东大会就与本次交易相关的议案进行审议。(gc/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-23 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1406096/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK0183","BK0196","BK1161","BK1191","600196","BK0060","02696","BK0188","BK1593","02196","BK0187","BK0012","BK0096","BK0239","BK0175","BK0028"],"gpt_icon":0},{"id":"2493630477","title":"复星医药（600196）股东上海复星高科技(集团)有限公司质押1.98亿股，占总股本7.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2493630477","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493630477?lang=zh_cn&edition=full","pubTime":"2024-12-23 22:15","pubTimestamp":1734963325,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药12月23日公开信息显示，股东上海复星高科技(集团)有限公司向中国工商银行股份有限公司上海市长宁支行合计质押1.98亿股，占总股本7.41%。质押详情见下表：截止本公告日，股东上海复星高科技(集团)有限公司已累计质押股份7.12亿股，占其持股总数的79.99%。复星医药主营业务：制药、医疗器械与医学诊断、医疗健康服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122300034665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0196","600196","BK0188","BK0028","BK1191","BK0183","BK1515","BK0239","BK0060","BK1593","BK0175","BK0096","BK0187","02196"],"gpt_icon":0},{"id":"2493542732","title":"复星医药(02196)控股股东复星高科技质押1.98亿股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2493542732","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493542732?lang=zh_cn&edition=full","pubTime":"2024-12-23 18:08","pubTimestamp":1734948507,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)公布，于 2024 年 12 月 23 日接到控股股东复星高科技的通知，其已将所持有公司的部分 A 股股份办理质押手续，涉及质押1.98亿股公司股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","600196","BK0175","02196","BK0060","BK0183","BK0188","BK1593","BK1191","BK0187","BK0196","BK0096","BK1515","BK0012","BK0239"],"gpt_icon":0},{"id":"2493734497","title":"复星医药：股东复星高科技部分股份质押","url":"https://stock-news.laohu8.com/highlight/detail?id=2493734497","media":"观点网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493734497?lang=zh_cn&edition=full","pubTime":"2024-12-23 17:18","pubTimestamp":1734945480,"startTime":"0","endTime":"0","summary":"观点网讯：12月23日，复星医药发布公告，披露了股东复星高科技部分股份质押的相关信息。公告显示，复星高科技作为控股股东，持有复星医药股份总数约为35.99%，其中A股889890955股，H股71533500股。复星高科技及其一致行动人合计持股967812180股，约占公司股份总数的36.23%。本次股份质押后，复星高科技 及其一致行动人质押本公司股份数量余额为 711800000 股，约占截至当日复星高科技及其一致行动人所持有本公司股份数的73.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223175411ab8da657&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223175411ab8da657&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1593","02196","BK1191"],"gpt_icon":0},{"id":"2493732283","title":"复星医药：为子公司累计提供319亿融资担保","url":"https://stock-news.laohu8.com/highlight/detail?id=2493732283","media":"观点网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493732283?lang=zh_cn&edition=full","pubTime":"2024-12-23 17:12","pubTimestamp":1734945120,"startTime":"0","endTime":"0","summary":"观点网讯：12月23日，复星医药发布关于为控股子公司提供担保的进展公告。截至公告日，包括本次担保在内，复星医药累计对外担保金额约319.07亿，占上市公司股东净资产的69.84%，无逾期担保事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223175248a2046923&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223175248a2046923&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1593","BK1191"],"gpt_icon":0},{"id":"2493427085","title":"重磅药品种抢滩！石四药第三家过评，奥赛康、豪森、复星等积极布局，诺华能否抗住冲击？","url":"https://stock-news.laohu8.com/highlight/detail?id=2493427085","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493427085?lang=zh_cn&edition=full","pubTime":"2024-12-23 09:52","pubTimestamp":1734918762,"startTime":"0","endTime":"0","summary":"业内观点认为，石四药作为国内第三家获批地拉罗司分散片仿制药的企业，将直接参与分割原研药的国内市场份额，并与此前已经获批的江苏奥赛康药业和中美华世通生物医药掀起新一轮市场竞争；此外，包括江苏豪森、复星医药等在内的国内巨头药企均在积极推进产品布局。2022年5月13日，NMPA发布药品批准证明文件待领取信息，其中，江苏豪森药业两款仿制药品种获批上市，分别为地拉罗司片和氢溴酸伏硫西汀片。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223095707ab8c9c8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223095707ab8c9c8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","02196","02005","BK1515","BK1191"],"gpt_icon":0},{"id":"2493443042","title":"复宏汉霖将完成私有化：拟明年2月初退市 成复星旗下又一摘牌企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2493443042","media":"雷递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493443042?lang=zh_cn&edition=full","pubTime":"2024-12-22 22:03","pubTimestamp":1734876201,"startTime":"0","endTime":"0","summary":"雷递网 雷建平 12月22日在宝宝树被强制退市，复星旅文宣布要私有化之际，复星旗下上市企业复宏汉霖的私有化也取得积极进展。截至今日，复宏汉霖股价为23.9港元，市值为129.9亿港元。截至目前，复宏汉霖处于停牌阶段，公司股价为18.84港元，市值为102亿港元。复星旅文称，此次私有化提案是基于复星旅文长期发展战略所做出的关键决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222221641a202489a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222221641a202489a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161","BK1191","02196","BK1593","BK1515"],"gpt_icon":0},{"id":"2493107842","title":"复星医药寄发有关以吸收合并复宏汉霖并私有化的文件","url":"https://stock-news.laohu8.com/highlight/detail?id=2493107842","media":"观点网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493107842?lang=zh_cn&edition=full","pubTime":"2024-12-22 18:34","pubTimestamp":1734863640,"startTime":"0","endTime":"0","summary":"观点网讯：12月22日，上海复星医药（集团）股份有限公司、上海复宏汉霖生物技术股份有限公司发布联合公告，宣布寄发有关以吸收合并复宏汉霖方式，由复星新药对复宏汉霖私有化建议的综合文件。根据公告，综合文件已于同日寄发，详细阐述了私有化的具体条款和条件。此次私有化临时股东大会及H股类别股东大会的日期定于2025年1月22日，股份过户登记手续将从2025年1月17日暂停至同月22日。经独立董事委员会批准，董事会已委任浤博资本有限公司为独立财务顾问，以就合并向独立董事委员会提供意见 。预计所有生效条件将在2025年1月22日达成，届时H股在联交所的最后交易日为2025年2月4日下午4时10分。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222184108ab8b37e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241222184108ab8b37e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","600196","BK1191","BK1515","02696","BK1593","02196"],"gpt_icon":0},{"id":"2492458667","title":"南向资金12月19日净买入复星医药74.10万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2492458667","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492458667?lang=zh_cn&edition=full","pubTime":"2024-12-20 09:30","pubTimestamp":1734658219,"startTime":"0","endTime":"0","summary":"12月19日, 南向资金增持复星医药74.10万股，连续3日增持。截止当日收盘，港股通共持有复星医药30943.60万股，占流通股56.05%。港股通增持金额前五个股分别为建设银行、中国移动、中国海洋石油、工商银行、农业银行。复星医药近5个交易日下跌4.12%，港股通累计增持238.15万股；近20个交易日下跌3.99%，港股通累计增持629.09万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220093610ab85b0a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220093610ab85b0a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","02196","BK1191","BK1593","600196"],"gpt_icon":0},{"id":"2492120570","title":"复星医药子公司复宏汉霖与Palleon签署许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492120570","media":"北京商报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492120570?lang=zh_cn&edition=full","pubTime":"2024-12-19 20:57","pubTimestamp":1734613061,"startTime":"0","endTime":"0","summary":"12月19日晚间，复星医药发布公告称，公司控股子公司复宏汉霖与Palleon签订《合作与许可协议》，根据约定，双方将基于各自专利及专有技术，就Palleon在研产品E-602及相关联合治疗方案于领域内的全球合作开发及于各自许可区域内的商业化开展合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219210704a1fb320f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219210704a1fb320f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1515","02696","BK1191","02196","BK1161"],"gpt_icon":0},{"id":"2492140822","title":"复星医药(600196.SH)与Palleon签订合作与许可协议 拟开展许可产品联合汉利康®临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2492140822","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492140822?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:27","pubTimestamp":1734604060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，公司控股子公司复宏汉霖与Palleon签订《合作与许可协议》，根据约定，双方将基于各自专利及专有技术，就Palleon在研产品E-602及相关联合治疗方案于领域内的全球合作开发及于各自许可区域内的商业化开展合作。截至本公告日期，许可产品用于治疗晚期癌症患者的I/II期临床试验正由Palleon于美国开展。复宏汉霖拟于《合作与许可协议》签订后，开展许可产品联合汉利康用于治疗狼疮肾炎的临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0028","BK0096","BK0175","BK1593","BK0183","BK1515","BK0188","BK0196","600196","BK0239","BK0060","BK0187","BK1191","02196"],"gpt_icon":0},{"id":"2492147708","title":"复星医药：控股子公司签署药品合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492147708","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492147708?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:27","pubTimestamp":1734604032,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0187","BK1583","BK1576","BK0188","BK0239","BK1141","BK0196","BK1161","BK1593","BK0012","02696","BK0060","BK0183","BK0175","BK1515","03347","BK1191","600196","BK0096","02196","BK0028"],"gpt_icon":0},{"id":"2492128609","title":"复星医药与Palleon签署全球合作协议 预计支付至多5280万美元开发费","url":"https://stock-news.laohu8.com/highlight/detail?id=2492128609","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492128609?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:27","pubTimestamp":1734604020,"startTime":"0","endTime":"0","summary":"2024年12月19日，公司控股子公司复宏汉霖与Palleon签订《合作与许可协议》，双方将基于各自专利及专有技术，就Palleon在研产品E-602及相关联合治疗方案进行全球合作开发及商业化。根据协议，复宏汉霖将向Palleon支付合计至多5280万美元的开发里程碑款，并在许可产品的销售中支付特许权使用费，比例在8%至12%之间。2024年前三季度，复星医药实现收入309.12亿元，归母净利润20.11亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219183742ab8431f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219183742ab8431f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","600196","BK0012","BK0175","BK0183","BK0096","BK0239","BK0060","02196","BK0187","BK0196","BK0188"],"gpt_icon":0},{"id":"2492147795","title":"复星医药最新公告：控股子公司复宏汉霖与Palleon签署许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492147795","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492147795?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:21","pubTimestamp":1734603679,"startTime":"0","endTime":"0","summary":"复星医药公告，控股子公司复宏汉霖与Palleon签订《合作与许可协议》，双方将基于各自专利及专有技术，就Palleon在研产品E-602及相关联合治疗方案于领域（即用于人类疾病治疗）内的全球合作开发及于各自许可区域内的商业化开展合作。E-602是一种唾液酸酶融合蛋白，拟用于肿瘤以及自身免疫类疾病的治疗。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121900031654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK1515","02696","BK0096","BK0188","BK0012","BK0196","BK0183","BK1593","BK0175","02196","BK1161","BK0060","BK0028","BK0239","BK1191","600196"],"gpt_icon":0},{"id":"2492555147","title":"复星医药：子公司复宏汉霖与Palleon签订合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2492555147","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492555147?lang=zh_cn&edition=full","pubTime":"2024-12-19 18:16","pubTimestamp":1734603364,"startTime":"0","endTime":"0","summary":"复星医药12月19日公告，12月19日，公司控股子公司复宏汉霖与Palleon签订《合作与许可协议》，根据约定，双方将基于各自专利及专有技术，就Palleon在研产品E-602及相关联合治疗方案于领域（即用于人类疾病治疗）内的全球合作开发及于各自许可区域内的商业化开展合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219181604a1fae3a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219181604a1fae3a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1593","BK1191","02196","BK1161","02696"],"gpt_icon":0},{"id":"2492591006","title":"复星医药（600196）12月17日主力资金净买入706.15万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492591006","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492591006?lang=zh_cn&edition=full","pubTime":"2024-12-18 08:18","pubTimestamp":1734481120,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月17日收盘，复星医药报收于25.96元，上涨0.43%，换手率0.55%，成交量11.58万手，成交额3.01亿元。近5日资金流向一览见下表：复星医药融资融券信息显示，融资方面，当日融资买入1579.58万元，融资偿还2315.03万元，融资净偿还735.46万元。复星医药主营业务：制药、医疗器械与医学诊断、医疗健康服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121800008453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0196","600196","BK0188","BK0028","BK1191","BK0183","BK1515","BK0239","BK0060","BK1593","BK0175","BK0096","BK0187","02196"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":0.0014},{"period":"3month","weight":0.0919},{"period":"6month","weight":0.0903},{"period":"1year","weight":-0.1132},{"period":"ytd","weight":-0.156}],"compareEarnings":[{"period":"1week","weight":0.0202},{"period":"1month","weight":0.0452},{"period":"3month","weight":0.0507},{"period":"6month","weight":0.1344},{"period":"1year","weight":0.23},{"period":"ytd","weight":0.179}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司经营五个分部。制药分部主要从事创新药、成熟医药产品制造和疫苗业务。医疗器械与医学诊断分部主要从事分子诊断、免疫诊断、微生物诊断等医疗美容器械的制造和销售。医疗健康服务分部主要从事线上线下一体化医疗服务平台的经营。医药分销和零售分部主要从事医药产品的批发零售。其他分部从事其他医药相关业务。该公司的产品主要用于肿瘤、免疫、中枢神经等治疗领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.049472},{"month":2,"riseRate":0.75,"avgChangeRate":0.030189},{"month":3,"riseRate":0.666667,"avgChangeRate":0.053895},{"month":4,"riseRate":0.416667,"avgChangeRate":0.038772},{"month":5,"riseRate":0.416667,"avgChangeRate":0.023544},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.030979},{"month":7,"riseRate":0.583333,"avgChangeRate":0.016786},{"month":8,"riseRate":0.25,"avgChangeRate":-0.056338},{"month":9,"riseRate":0.416667,"avgChangeRate":-0.002922},{"month":10,"riseRate":0.5,"avgChangeRate":0.028405},{"month":11,"riseRate":0.461538,"avgChangeRate":0.046299},{"month":12,"riseRate":0.461538,"avgChangeRate":0.021004}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}